Trial · NCT04082442

Evolocumab in Patients With Acute MI

NCT04082442, Phase 2, Completed, Johns Hopkins University; results first posted 2025-10-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Evolocumab in Patients With Acute MI. Trials, record NCT04082442. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04082442

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Evolocumab in Patients With Acute MI
NCT number: NCT04082442
Status: Completed
Phases: Phase 2
Enrollment: 100 participants, actual
Lead sponsor: Johns Hopkins University
Conditions: Acute Coronary Syndrome
Interventions: Evolocumab, Placebos
First posted: 2019-09-09
Last updated: 2025-10-23
Results first posted: 2025-10-23

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in LDL-Cholesterol	Baseline, 25-30 days	The difference, in the percent change in LDL-cholesterol (mg/dL), from baseline to the 25-30 day values.
Secondary	FDG-PET Imaging Analysis of Inflammation as Mean Standardized Uptake Value (SUV)	Baseline, 30 days	The change between early infarction period and thirty day assessments of PET-FDG assessed myocardial inflammation. A higher SUV value= worse inflammation. There are no standard values for this, since this study is the first to describe this in this patient population.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in LDL-Cholesterol	Baseline, 25-30 days		percent change mg/dL	MEAN
SECONDARY	FDG-PET Imaging Analysis of Inflammation as Mean Standardized Uptake Value (SUV)	Baseline, 30 days	participants who completed the follow-up scan at 30 days	Standardized Uptake Value (SUV)	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in LDL-Cholesterol	Evolocumab	-70.59	95% Confidence Interval -82 to -58.21	percent change mg/dL
Change in LDL-Cholesterol	Placebo	-44.78	95% Confidence Interval -58.43 to -6.34	percent change mg/dL
FDG-PET Imaging Analysis of Inflammation as Mean Standardized Uptake Value (SUV)	Evolocumab	-26.21	Standard Deviation 22.61	Standardized Uptake Value (SUV)
FDG-PET Imaging Analysis of Inflammation as Mean Standardized Uptake Value (SUV)	Placebo	-14.52	Standard Deviation 36.92	Standardized Uptake Value (SUV)

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Evolocumab	50
Overall Study	STARTED	Placebo	50
Overall Study	COMPLETED	Evolocumab	27
Overall Study	COMPLETED	Placebo	29
Overall Study	NOT COMPLETED	Evolocumab	23
Overall Study	NOT COMPLETED	Placebo	21

Source ClinicalTrials.gov

Adverse events22

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Episode of NSVT	Cardiac disorders	Evolocumab	1	50
other	Episode of NSVT	Cardiac disorders	Placebo	0	50
other	Atrial fibrilation	Cardiac disorders	Evolocumab	0	50
other	Atrial fibrilation	Cardiac disorders	Placebo	1	50
other	Recurrent Ischemia	Cardiac disorders	Evolocumab	1	50
other	Recurrent Ischemia	Cardiac disorders	Placebo	0	50
other	Dyspepsia and constipation	Gastrointestinal disorders	Evolocumab	0	50
other	Dyspepsia and constipation	Gastrointestinal disorders	Placebo	1	50
other	Hypotension	Vascular disorders	Evolocumab	1	50
other	Hypotension	Vascular disorders	Placebo	0	50

1 to 10 of 22Source ClinicalTrials.gov

See all 22 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Evolocumab	0	50
Total, all-cause mortality	Placebo	0	50
Total, other adverse events	Evolocumab	4	50
Total, other adverse events	Placebo	2	50
Total, serious adverse events	Evolocumab	3	50
Total, serious adverse events	Placebo	5	50

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
35314069	DERIVED	PubMed
37095769	DERIVED	PubMed
40780143	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Evolocumab vs Placebo: deaths from any cause	Trial comparisons
Evolocumab vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04082442

GET https://conductscience.org/api/trials/v1/NCT04082442/events?page=2

API reference For AI assistants